BPC-157 + TB-500 in One Vial? Not Under the HHS Policy
The HHS enforcement discretion policy covers both peptides, but only as separate single-ingredient products. Here is what that means for the "Wolverine stack," which routes each peptide is covered for, and what the evidence says about combining them.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
What the HHS Policy Says About Blends
The policy only covers a compounded product that contains a single active ingredient from Appendix A. Frier Levitt notes this rules out BPC-157 plus TB-500 in one product, and also rules out pairing a listed peptide with a non-peptide ingredient.
Appendix B lists BPC-157 acetate for subcutaneous, intramuscular, oral and topical use, and TB-500 acetate for subcutaneous or intramuscular injection only. The only device allowed in the package is an FDA 510(k)-cleared syringe.
Coverage applies to state-licensed pharmacies, Federal facilities and licensed physicians compounding under section 503A against a valid patient-specific prescription. Trade summaries say 503B outsourcing facilities are not covered.
HHS says it does not intend to take enforcement action while FDA develops the 503A bulks list through rulemaking. The notice says compounded drugs are not FDA-approved and the policy is not binding on HHS or the public.
What the Data Shows
What the Viral Posts Got Right, and What They Skip
| What went viral on X | What the policy and its summaries say |
|---|---|
| "BPC-157 cannot share a bottle with TB-500." | Correct. The policy covers only compounded products with a single active ingredient from Appendix A. Frier Levitt's analysis gives this exact pair as its example: a product combining BPC-157 and TB-500 falls outside the policy even though each peptide is on the list. |
| "So they are sold separately." | Separate single-peptide products are the only form the policy describes. Each one still needs a patient-specific prescription, a state-licensed 503A pharmacy, bulk powder from an FDA-registered manufacturer with a certificate of analysis, and the label line "This is a compounded drug product. Not for resale." |
| "The Wolverine stack is legal now." | No. HHS describes enforcement discretion, not approval or legalization. The notice says compounded drugs are not FDA-approved, that the policy is not binding, and that HHS may revisit it if a safety signal or product-quality issue arises. |
| "Any route works, same as before." | Routes are limited per peptide. TB-500 is covered for subcutaneous or intramuscular injection only. Intravenous use is not among the routes listed for any of the six. |
Which Routes Does the Policy Cover for Each Peptide?
BPC-157 and TB-500 overlap on two routes only: subcutaneous and intramuscular injection. Appendix B ties each peptide to a specific salt form and route list, so a familiar peptide name does not cover every form a supplier sells.
| Peptide (Appendix B identity) | Routes covered by the policy | Notes |
|---|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, topical | Oral products need documentation of adequate bioavailability |
| TB-500 acetate | Subcutaneous or intramuscular injection | No oral or topical form covered |
| MOTS-c acetate | Subcutaneous or intramuscular injection | |
| Epitalon acetate | Subcutaneous or intramuscular injection | Dispensed in intermittent courses |
| KPV acetate | Topical and oral | Injectable KPV is outside the listed routes |
| Semax free base | Intranasal | Injectable Semax is outside the listed routes |
Regulatory sources: HHS Federal Register notice 2026-22192 (Docket HHS-OASH-2026-0496), the HHS policy appendix, and published analyses by Frier Levitt, BakerHostetler, Hyman, Phelps & McNamara (FDA Law Blog), Drug Topics and Lachman Consultants, Oct 28-29, 2026. Route and condition details come from those summaries of the appendix; check the current HHS document before relying on them.
Does Stacking BPC-157 With TB-500 Work Better?
The "Wolverine stack" pitch is that the two peptides add up. The only study we found that tested the pair head to head against each peptide alone did not show that. In a 2026 rat study, 32 rats had their Achilles tendon cut and repaired, then got BPC-157, TB-500, both, or nothing by intraperitoneal injection for four weeks (8 rats per group). TB-500 alone gave the only statistically significant gain in load to failure. The TB-500 and combination groups had better Movin tissue scores than controls, and the authors reported that the combination "did not confer additional benefits compared to either agent alone" (PMID 42542926).
That is one small animal study, so it does not settle the question either way. Human data are thinner still. A 2026 systematic review found three human BPC-157 studies with 30 people in total, all of poor methodological quality and very low certainty (PMID 42885452). A 2026 orthopaedic review found no controlled human orthopaedic efficacy evidence for BPC-157, thymosin beta-4 or TB-500, and noted that TB-500 is a seven amino-acid fragment of thymosin beta-4 that is often conflated with the full-length protein (PMIDs 42937313, 22962027). A 2026 sports medicine review reached a similar view: many unapproved peptides look good in animal models, but rigorous human safety data are scarce (PMID 41966639). We found no human trial of the two peptides used together.
Key Takeaways
- HHS published an enforcement discretion policy for six peptides, including BPC-157 and TB-500 (Federal Register document 2026-22192, filed October 28, 2026).
- The policy covers only compounded products with a single active ingredient from its list, so a BPC-157 and TB-500 blend in one vial falls outside it.
- TB-500 acetate is covered for subcutaneous or intramuscular injection only; BPC-157 acetate also covers oral and topical forms.
- Each product needs a patient-specific prescription and a state-licensed 503A pharmacy using bulk powder from an FDA-registered manufacturer with a certificate of analysis.
- In a 2026 rat Achilles tendon study, combining BPC-157 and TB-500 gave no additional benefit over either peptide alone (PMID 42542926).
- Human BPC-157 evidence is three small studies with 30 people in total, rated very low certainty (PMID 42885452).
- Whether FDA rulemaking will add BPC-157 or TB-500 to the 503A bulks list, and when.
- How long the interim policy will last, or whether HHS will revisit it.
- Whether BPC-157 and TB-500 together do anything in humans. We found no human trial of the combination.
- Whether the two peptides are stable or compatible when mixed. We found no published study on it.
- How individual state boards of pharmacy will apply the federal policy.
- Long-term human safety of either peptide.
Frequently Asked Questions
Can BPC-157 and TB-500 be compounded in one vial under the HHS policy?
No. The HHS enforcement discretion policy only covers compounded products that contain a single active ingredient from its Appendix A list. Frier Levitt's analysis uses this exact pair as its example: a product combining BPC-157 and TB-500 is outside the policy even though both peptides are on the list. A pharmacy that blends them would not have the policy's cover.
Is the Wolverine stack legal now?
Not in the sense most posts imply. HHS said it does not intend to take enforcement action against state-licensed 503A pharmacies and physicians that compound BPC-157 or TB-500 as separate single-ingredient products and meet the policy's conditions. That is enforcement discretion, not FDA approval. The notice says the policy is not binding and may be revisited. A premixed "Wolverine" blend is not covered.
Which routes are covered for BPC-157 and TB-500?
Published summaries of Appendix B list BPC-157 acetate for subcutaneous, intramuscular, oral and topical dosage forms, with bioavailability documentation required for oral products. TB-500 acetate is listed for subcutaneous or intramuscular injection only. Intravenous use is not among the listed routes for any of the six peptides.
Does combining BPC-157 and TB-500 work better than either alone?
There is no human evidence either way. The one controlled study we found that compared the pair with each peptide alone was in rats: after Achilles tendon repair, the combination did not add benefit over either agent alone, and TB-500 alone gave the only significant strength gain (PMID 42542926). One small rat study cannot settle it, but it does not support the stacking claim.
Does the policy cover research-use-only Wolverine blends?
No. The policy covers state-licensed pharmacies, Federal facilities and licensed physicians compounding against a prescription. Blends sold as research chemicals "not for human use" sit outside it. HHS said the policy is meant to discourage the widespread use of research-use-only peptides from foreign manufacturers, according to the policy text quoted by Lachman Consultants.
Research-Use-Only BPC-157 (Not the Prescription Route)
This is not a prescription and not a state-licensed 503A pharmacy. Research-use-only vials are sold "not for human use" and sit outside the HHS policy described above. This is BPC-157 on its own, not a blend. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
View Research-Grade BPC-157 at Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
Reading a certificate of analysis, vendor evaluation, pricing, supplies and storage. No dosing schedules, no protocols.
The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
This page describes a federal enforcement policy, not legal advice. HHS calls the policy interim and non-binding, and state pharmacy law still applies. Compounded drugs are not FDA-approved. Talk to a licensed clinician before starting any peptide.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.